A New Era for Heart Health: PARCC and POLYGON Therapeutics Collaborative R&D Unit
In a strategic move, PARCC has partnered with POLYGON Therapeutics to host their early Research and Development (R&D) unit at our center. This collaboration, born from the groundbreaking work of Professor Hafid Ait-Oufella (Team Leader at PARCC), is set to significantly accelerate the creation of novel treatments for cardiovascular diseases, addressing a global health challenge that claims 18 million lives annually.
By housing POLYGON’s R&D efforts within PARCC, the partnership will harness our renowned infrastructure, cutting-edge technologies, and network of leading cardiovascular experts. This synergy will empower POLYGON to enhance its research capabilities and more rapidly translate scientific discoveries into life-changing therapies.
“We are delighted to join forces with PARCC… This collaboration represents a significant step forward in our mission to revolutionize cardiovascular disease treatments and improve patient outcomes,” said Mohamed Abou Ali, CEO of POLYGON Therapeutics. Professor Ait-Oufella, Chief Scientific Officer at POLYGON, shared his enthusiasm: “It is very exciting to see the potential clinical application of our experimental research come to fruition.”
About POLYGON Therapeutics:
POLYGON Therapeutics is a French biotech company developing innovative drugs to treat patients suffering from cardiovascular diseases and acute immune disorders. Its main drug is afirst-in-class monoclonal antibody, PLG-101.
Cardiovascular Diseases (CVDs) are the number 1cause of death globally: in recent times, 18 million people have died annually from CVDs, representing 31% of all global deaths. Among these deaths, 85% are due to heart attacks and strokes. Despite a better management of risk factors (e.g. hypercholesterolemia and hypertension) and significant progress in CVD care, new therapeutic approaches remain untapped.
POLYGON’s first therapeutic solution, PLG-101,aims to target a specific immune response happening during myocardial infarction to enhance post-ischemic cardiac remodeling. It has already shown successful results on preclinical models. Potential in other cardiovascular indications has been highlighted.
